Adventitia contribution in vascular tone: insights from adventitia‐derived cells in a tissue‐engineered human blood vessel

Whether the adventitia component of blood vessels directly participates in the regulation of vascular tone remains to be demonstrated. We have recently developed a human tissue‐engineered blood vessel comprising the three tunicae of a native blood vessel using the self‐assembly approach. To investigate the role of the adventitia in the modulation of vascular tone, this tissue‐engineering method was used to produce three vascular constructs from cells explanted and proliferated from donor vessel tunicae 1) an adventitia + a media, or only 2) an adventitia, or 3) a media. The vasoconstriction responses of these 3 constructs to endothelin, the most potent vasopressor known up‐to‐date, as well as to nonselective and selective agonists and antagonists, were compared. The adventitia contracted to endothelin‐1, ‐2, whereas the media and the media+ adventitia contracted to all three endothelins. Endothelin‐induced contraction of the adventitia was dependent on ETA receptors, whereas that of the media and the adventitia+ media was ETA and ETB receptor‐dependent. RT‐PCR studies corroborated these results. SNP induced a dose‐dependent relaxation of the three tissue constructs. We also demonstrated that the endothelin‐converting enzyme, responsible for the formation of the active endothelin peptides, was present and functional in the adventitia. In conclusion, this is the first direct demonstration that the adventitia has the capacity to contract and relax in response to vasoactive factors. The present study suggests that the adventitia of a blood vessel could play a greater role than expected in the modulation of blood vessel tone.—Laflamme, K., Roberge, C. J., Grenier, G., Rémy‐Zolghadri, M., Pouliot, S., Baker, K., Labbé, R., D'Orleans‐Juste, P., Auger, F. A., Germain, L. Adventitia contribution in vascular tone: insights from adventitia‐derived cells in a tissue‐engineered human blood vessel. FASEB J. 20, E516–E524 (2006)

[1]  D. Heistad,et al.  Blood flow through new microvessels: factors that affect regrowth of vasa vasorum. , 1988, The American journal of physiology.

[2]  S. Moncada,et al.  Nitric oxide: physiology, pathophysiology, and pharmacology. , 1991, Pharmacological reviews.

[3]  J. Blanc,et al.  Constrictive perivenous mesh prosthesis for preservation of vein integrity. Experimental results and application for coronary bypass grafting. , 1986, The Journal of thoracic and cardiovascular surgery.

[4]  P. D'Orléans-Juste,et al.  Synthesis and degradation of endothelin-1. , 2003, Canadian journal of physiology and pharmacology.

[5]  J. R. Lancaster.  A tutorial on the diffusibility and reactivity of free nitric oxide. , 1997, Nitric oxide : biology and chemistry.

[6]  D. Harrison,et al.  Nitric oxide generation from nitroprusside by vascular tissue. Evidence that reduction of the nitroprusside anion and cyanide loss are required. , 1991, Biochemical pharmacology.

[7]  K. Tanzawa,et al.  Cloning and functional expression of human endothelin-converting enzyme cDNA. , 1995, Biochemical and biophysical research communications.

[8]  L. Olson,et al.  Selective guanylyl cyclase inhibitor reverses nitric oxide-induced vasorelaxation. , 1997, Hypertension.

[9]  P. Mulder,et al.  Nonpeptidic endothelin-converting enzyme inhibitors and their potential therapeutic applications. , 2002, Canadian journal of physiology and pharmacology.

[10]  P. Vallance,et al.  Endothelin alters the reactivity of vasa vasorum: mechanisms and implications for conduit vessel physiology and pathophysiology , 1999, British journal of pharmacology.

[11]  J. Michel,et al.  Selective isolation of rat aortic wall layers and their cell types in culture--application to converting enzyme activity measurement. , 1994, Tissue & cell.

[12]  A. Hachiya,et al.  Biochemical Characterization of Endothelin-converting Enzyme-1α in Cultured Skin-derived Cells and Its Postulated Role in the Stimulation of Melanogenesis in Human Epidermis* , 2002, The Journal of Biological Chemistry.

[13]  J. Martin,et al.  The adventitia, endothelium and atherosclerosis. , 1997, International journal of microcirculation, clinical and experimental.

[14]  D. Webb,et al.  Contribution of endogenous generation of endothelin-1 to basal vascular tone , 1994, The Lancet.

[15]  W. Bax,et al.  Heterogeneity of endothelin/sarafotoxin receptors mediating contraction of the human isolated saphenous vein. , 1993, European journal of pharmacology.

[16]  S. Nakanishi,et al.  Cloning and expression of a cDNA encoding an endothelin receptor , 1990, Nature.

[17]  C. J. Schwartz,et al.  Cellular Infiltration of the Human Arterial Adventitia Associated with Atheromatous Plaques , 1962, Circulation.

[18]  Sadao Kimura,et al.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells , 1988, Nature.

[19]  M. Yanagisawa,et al.  ECE-1: A membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1 , 1994, Cell.

[20]  Johannes A. G. Rhodin,et al.  Architecture of the Vessel Wall , 1980 .

[21]  S. Bertenshaw,et al.  Effect of phosphoramidon (endothelin converting enzyme inhibitor) and BQ-123 (endothelin receptor subtype A antagonist) on blood pressure in hypertensive rats. , 1993, American journal of hypertension.

[22]  P. Vallance,et al.  On the regulation of tone in vasa vasorum. , 1999, Cardiovascular research.

[23]  R. Cohen,et al.  Paracrine role of adventitial superoxide anion in mediating spontaneous tone of the isolated rat aorta in angiotensin II-induced hypertension. , 1999, Hypertension.

[24]  M. Fernández-Alfonso,et al.  Effect of removal of adventitia on vascular smooth muscle contraction and relaxation. , 2001, American journal of physiology. Heart and circulatory physiology.

[25]  R. Hetzer,et al.  The biocompound method in coronary artery bypass operations: surgical technique and 3-year patency. , 2000, The Annals of thoracic surgery.

[26]  G. Schmalzing,et al.  Molecular characterization of human and bovine endothelin converting enzyme (ECE‐1) , 1994, FEBS letters.

[27]  A. Jeng,et al.  Pharmacological profile of a non-peptidic dual inhibitor of neutral endopeptidase 24.11 and endothelin-converting enzyme. , 1994, Biochemical and biophysical research communications.

[28]  R. Bohle,et al.  Cellular Distribution of Endothelin-converting Enzyme-1 in Human Tissues , 1999, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[29]  P. Vallance,et al.  Human saphenous vein contains both endothelin ETA and ETB contractile receptors. , 1994, European journal of pharmacology.

[30]  F. Plum.  Handbook of Physiology. , 1960 .

[31]  R. Guignard,et al.  Isolation and culture of the three vascular cell types from a small vein biopsy sample , 2003, In Vitro Cellular & Developmental Biology - Animal.

[32]  M. Yanagisawa,et al.  The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[33]  D. Webb,et al.  Systemic ETA receptor antagonism with BQ‐123 blocks ET‐1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men , 2001, British journal of pharmacology.

[34]  L. Germain,et al.  Tissue-Engineered Human Vascular Media With a Functional Endothelin System , 2005, Circulation.

[35]  L. Germain,et al.  A human tissue‐engineered vascular media: a new model for pharmacological studies of contractile responses , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  A. Ergul,et al.  Gender differences in the expression of endothelin receptors in human saphenous veins in vitro. , 1998, The Journal of pharmacology and experimental therapeutics.

[37]  F A Auger,et al.  A completely biological tissue‐engineered human blood vessel , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  J. Wilcox,et al.  Potential role of the adventitia in arteritis and atherosclerosis. , 1996, International journal of cardiology.

[39]  T. Masaki,et al.  Pathophysiology of endothelin in the cardiovascular system. , 1999, Annual review of physiology.

[40]  E. Vicaut,et al.  ACE in three tunicae of rat aorta: expression in smooth muscle and effect of renovascular hypertension. , 1994, The American journal of physiology.